Flunixin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Flunixin
Accession Number
DB11518
Type
Small Molecule
Groups
Vet approved
Description

Flunixin is a non-steroidal anti-inflammatory drug for use in pigs, cattle and horses. It exerts analgesic and antipyretic effects. This drug is often prepared for use in meglumine salt form. Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian. Flunixin may be also referred to as Banamine, and other trade names.

Structure
Thumb
Synonyms
  • 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)-3-pyridinecarboxylic acid
  • Flunixin
  • Flunixine
  • Flunixino
  • Flunixinum
External IDs
SCH 14714
Product Ingredients
IngredientUNIICASInChI Key
Flunixin meglumine8Y3JK0JW3U42461-84-7MGCCHNLNRBULBU-WZTVWXICSA-N
Categories
UNII
356IB1O400
CAS number
38677-85-9
Weight
Average: 296.249
Monoisotopic: 296.077262091
Chemical Formula
C14H11F3N2O2
InChI Key
NOOCSNJCXJYGPE-UHFFFAOYSA-N
InChI
InChI=1S/C14H11F3N2O2/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12/h2-7H,1H3,(H,18,19)(H,20,21)
IUPAC Name
2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid
SMILES
CC1=C(C=CC=C1NC1=C(C=CC=N1)C(O)=O)C(F)(F)F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with (S)-Warfarin.
1-benzylimidazoleThe risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Flunixin.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Flunixin.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of hypertension can be increased when Flunixin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Flunixin.
4-hydroxycoumarinThe risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineThe risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Flunixin.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of hypertension can be increased when Flunixin is combined with 5-methoxy-N,N-dimethyltryptamine.
AbacavirFlunixin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Webbon PM, Woolliscroft GJ: Cautious use of flunixin advocated. Vet Rec. 1984 Jul 14;115(2):45. [PubMed:6474767]
  2. Dobromylskyj P: Intraoperative use of flunixin meglumine. Vet Rec. 1992 Nov 28;131(22):520. [PubMed:1300683]
  3. Elwood C, Boswood A, Simpson K, Carmichael S: Renal failure after flunixin meglumine administration. Vet Rec. 1992 Jun 27;130(26):582-3. [PubMed:1308097]
  4. Traub-Dargatz JL, Bertone JJ, Gould DH, Wrigley RH, Weiser MG, Forney SD: Chronic flunixin meglumine therapy in foals. Am J Vet Res. 1988 Jan;49(1):7-12. [PubMed:3354970]
  5. Hardie EM, Kolata RJ, Rawlings CA: Canine septic peritonitis: treatment with flunixin meglumine. Circ Shock. 1983;11(2):159-73. [PubMed:6416706]
  6. Jaussaud P: [Flunixin and its use in horses]. Ann Rech Vet. 1986;17(4):353-62. [PubMed:3493724]
  7. Hardie EM, Hardee GE, Rawlings CA: Pharmacokinetics of flunixin meglumine in dogs. Am J Vet Res. 1985 Jan;46(1):235-7. [PubMed:3970431]
  8. Ciofalo VB, Latranyi MB, Patel JB, Taber RI: Flunixin meglumine: a non-narcotic analgesic. J Pharmacol Exp Ther. 1977 Mar;200(3):501-7. [PubMed:850126]
  9. Hardee GE, Smith JA, Harris SJ: Pharmacokinetics of flunixin meglumine in the cow. Res Vet Sci. 1985 Jul;39(1):110-2. [PubMed:4035085]
  10. Smitherman P: Intra-operative use of flunixin meglumine. Vet Rec. 1992 Nov 14;131(20):471. [PubMed:1466125]
External Links
KEGG Drug
D04215
ChemSpider
34911
BindingDB
50201618
RxNav
25121
ChEBI
76138
ChEMBL
CHEMBL1617398
ZINC
ZINC000000001467
Wikipedia
Flunixin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0402 mg/mLALOGPS
logP4.17ALOGPS
logP3.69ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)1.88ChemAxon
pKa (Strongest Basic)5.38ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.22 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity70.97 m3·mol-1ChemAxon
Polarizability26.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0002-0090000000-70f9b31983f5288b8fea
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0090000000-92c4d99935c961396ae7
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0090000000-080bf40f3dcf0daaa83d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0lyo-0390000000-f93dbab44765f08c0dab
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-052f-0980000000-25f1566c97820e3a4a2e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-052f-0940000000-9954d8a5607714ddf5b8
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-1900000000-ccf143a90e816a424dc8
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01p9-4900000000-964033ab162c6602211d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03dr-9600000000-c91aeffcb76d5deb5560
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0090000000-6c7e03b24bf5feb5651e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0090000000-ae48aa44e601b23f0084
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0090000000-7c0fde19ae2a2a9c41e3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03fr-0090000000-17b52355cf235bfb3cc6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0290000000-af8ac4c2148d16e2d6f1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0090000000-1a92e6dc858763eada2d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0090000000-db80fa85855c5a1b0ea6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0090000000-6f29eea19f1a0079312e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01t9-0090000000-e441a6cc43bcb96a91e6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0290000000-54c443792e065716310d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0bti-0790000000-07ca5cb6f169826c16fa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a59-2920000000-bbf4b2222726f83a7484
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a5a-5900000000-2aec522ff8dac4251203
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-06rt-9600000000-2ffd8bd220d0979b5244

Taxonomy

Description
This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Trifluoromethylbenzenes
Direct Parent
Trifluoromethylbenzenes
Alternative Parents
Pyridinecarboxylic acids / Aniline and substituted anilines / Toluenes / Aminopyridines and derivatives / Imidolactams / Vinylogous amides / Heteroaromatic compounds / Amino acids / Secondary amines / Azacyclic compounds
show 8 more
Substituents
Trifluoromethylbenzene / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Aniline or substituted anilines / Aminopyridine / Toluene / Pyridine / Imidolactam / Heteroaromatic compound / Vinylogous amide
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, aminopyridine, pyridinemonocarboxylic acid (CHEBI:76138)

Drug created on February 26, 2016 10:31 / Updated on March 01, 2020 23:38

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates